Videos

Panelists discuss how they tailor treatment strategies for oligodendrogliomas and Grade 2 gliomas based on key clinical and molecular markers, with particular attention to insights from the CODEL trial and RTOG 9802 study.

Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing methods such as IHC and NGS.

Panelists discuss how comprehensive long-term monitoring protocols for patients who have received bispecific therapy typically involve regular follow-ups, standardized testing schedules, and clear communication channels between academic centers and community practices to manage potential complications and adverse events.

Panelists discuss how key areas for improvement in the application of GPRC5D-targeted therapies in real-world settings include optimizing patient selection, addressing logistical challenges, and enhancing adverse event management.

Panelists discuss how determining a patient's readiness to transition back to community oncology care after bispecific therapy involves assessing multiple factors including treatment response, toxicity resolution, overall stability, and the community practice's capabilities.

It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.

Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).

Panelists discuss how data from the long-term CARTITUDE-4 update reveal a notable rate of minimal residual disease (MRD) negativity with ciltacabtagene autoleucel, emphasizing its potential to enhance long-term outcomes in patients with lenalidomide-refractory multiple myeloma.

Panelists discuss how additional resources such as enhanced staff training, financial support, and improved patient education could benefit the implementation of bispecific therapies in community settings.

Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

With Eileen O’Reilly, MD, the Oncology Brothers discuss the current treatment paradigm for early-stage pancreatic cancer, focusing on diagnostic strategies, surgical options, and adjuvant therapies to improve patient outcomes.

With Eileen O’Reilly, MD, the Oncology Brothers discuss treatment considerations for resectable pancreatic cancer, including criteria for surgical resection, the role of adjuvant therapies, and strategies to optimize patient outcomes post surgery.

With Eileen O’Reilly, MD, the Oncology Brothers discuss the treatment paradigm for metastatic pancreatic cancer, covering systemic therapies, the role of targeted treatments, and strategies for managing disease progression and improving quality of life.

With Eileen O’Reilly, MD, the Oncology Brothers discuss treatment considerations for disease progression in pancreatic cancer, focusing on the management of refractory disease, shifting therapeutic strategies, and optimizing patient care in advanced stages.

With Eileen O’Reilly, MD, the Oncology Brothers discuss the essential steps in the initial workup for a newly diagnosed pancreatic cancer patient, including clinical evaluation, imaging, biopsy, and multidisciplinary staging for treatment planning.

Panelists discuss how prophylactic use of tocilizumab in the MajesTEC-1 trial may reduce the incidence and severity of cytokine release syndrome (CRS) in patients receiving bispecific antibody therapy for multiple myeloma, potentially improving treatment safety and tolerability.

The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.

Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.

Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.

Panelists discuss how patient-specific factors like age, comorbidities, cytogenetic risk status, and personal preferences guide decisions to deviate from standard protocols, with particular attention to frailty scores and organ function when considering treatment intensity.

Panelists discuss how the updated WHO classification system for gliomas has impacted their treatment approaches, while also addressing the practical difficulties of integrating these changes into routine clinical care.

Panelists discuss how a patient navigated her recurrent breast cancer diagnosis, detailing the symptoms, referral process, diagnostic tests, treatment considerations, and the concerns faced throughout the journey, while also examining the steps taken to confirm her HER2+ diagnosis.

Panelists provide a brief overview of breast cancer, discussing typical presentations of advanced breast cancer; key risk factors such as age, gender, and family history; various subtypes of the disease; and the essential steps in diagnosing, risk assessing, and staging patients.

Panelists discuss how the CARTITUDE-4 trial results show cilta-cel's superior efficacy over standard of care therapies in treating relapsed/refractory multiple myeloma, potentially reshaping treatment paradigms for this patient population.

Panelists discuss how the KarMMa-3 trial results demonstrate superior efficacy of ide-cel compared to standard of care therapies in patients with relapsed/refractory multiple myeloma, potentially establishing a new benchmark for treatment in this setting.

Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.

As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.